Sensory Neuron-Expressed TRPC4 Is a Target for the Relief of Psoriasiform Itch and Skin Inflammation in Mice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sang Hoon | - |
dc.contributor.author | Tonello, Raquel | - |
dc.contributor.author | Choi, Youngin | - |
dc.contributor.author | Jung, Sung Jun | - |
dc.contributor.author | Berta, Temugin | - |
dc.date.accessioned | 2022-07-07T11:13:46Z | - |
dc.date.available | 2022-07-07T11:13:46Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 0022-202X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/144402 | - |
dc.description.abstract | Psoriasis is an inflammatory skin disease associated with itch, which is a troublesome symptom with a few therapeutic options. TRPC4 is highly expressed in dorsal root ganglia (DRGs). Recently, we have revealed itch signaling in DRG neurons by which TRPC4 mediates itch to serotonergic antidepressants and demonstrated the antipruritic effect of the TRPC4 inhibitor ML204. However, the role of TRPC4 in acute and chronic itch is still largely unknown. Here, we have characterized the expression of TRPC4 in peptidergic DRG neurons and showed that acute itch induced by serotonin and histamine was attenuated in Trpc4-knockout mice and ML204-treated mice. We have also shown that silencing TRPC4 in DRG and its inhibition by intradermal injections were also effective in decreasing psoriatic itch after the repeated application of imiquimod, which is a preclinical model of psoriasis. Of clinical relevance, intradermal injections of ML204 in psoriasiform skin significantly reversed imiquimod-established chronic itch and cutaneous inflammation. Given that TRPC4 is expressed in human DRGs and a specific inhibitor is in clinical trials, our data not only expand our understanding of itch and psoriasis, but also reveal TRPC4 as a potential therapeutic target with considerable translational benefits. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Sensory Neuron-Expressed TRPC4 Is a Target for the Relief of Psoriasiform Itch and Skin Inflammation in Mice | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Tonello, Raquel | - |
dc.contributor.affiliatedAuthor | Jung, Sung Jun | - |
dc.identifier.doi | 10.1016/j.jid.2020.03.959 | - |
dc.identifier.scopusid | 2-s2.0-85085591707 | - |
dc.identifier.wosid | 000581092200022 | - |
dc.identifier.bibliographicCitation | JOURNAL OF INVESTIGATIVE DERMATOLOGY, v.140, no.11, pp.2221 - 2229 | - |
dc.relation.isPartOf | JOURNAL OF INVESTIGATIVE DERMATOLOGY | - |
dc.citation.title | JOURNAL OF INVESTIGATIVE DERMATOLOGY | - |
dc.citation.volume | 140 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2221 | - |
dc.citation.endPage | 2229 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | PRURITUS | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | PATHOGENESIS | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | POTENT | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordPlus | PAIN | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0022202X20313725?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.